SLU-PP-332
Last reviewed September 26, 2026
SLU-PP-332 is studied as an agonist of estrogen-related receptors, a family associated with the metabolic adaptations that follow endurance exercise.
Mechanism of action
Research investigates SLU-PP-332 for pan-ERR agonism, studied for effects on mitochondrial biogenesis and the shift toward oxidative metabolism seen in trained tissue.
- ERR AgonismStudied for activity across estrogen-related receptors that govern oxidative metabolic programmes.
- Exercise MimeticExplored for whether it reproduces aspects of the metabolic signature of endurance training.
- Route studied
- Subcutaneous
- Research status
- Preclinical
Published research on SLU-PP-332 consists of animal and in vitro studies, and no human clinical trials appear among the available citations.
What the research covers
What research examines
- Aerobic exercise capacity in animal models
- Metabolic syndrome in animal models
- Mitochondrial function and inflammation in the aging kidney
- Cardiac fatty acid metabolism in heart failure models
- Age-related muscle atrophy associated with inactivity
Reported effects in studies
- Human safety data are limited; no controlled human studies are available
- Adverse events are not summarized in the cited animal studies
- Subject of in vitro metabolite research for doping-control purposes
What research protocols have used
Research protocols have used 500–1,500 mcg per administration, once daily (morning, fasted), in 8-week blocks with 4 weeks off.
For research use only. These figures summarize published research protocols. They are not instructions or medical advice.
Every CoreX order ships with a per-lot protocol guide.
Open the reconstitution calculatorResearched alongside
Cited research
- Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity.
ACS chemical biology · 2023 · PubMed 36988910
- A Synthetic ERR Agonist Alleviates Metabolic Syndrome.
The Journal of pharmacology and experimental therapeutics · 2024 · PubMed 37739806
- Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney.
The American journal of pathology · 2023 · PubMed 37717940
- Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling.
International journal of biological macromolecules · 2026 · PubMed 41850449
- Analysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist for Doping-Control Purposes.
Drug testing and analysis · 2026 · PubMed 41688415
Questions about SLU-PP-332
SLU-PP-332 is a synthetic research compound studied as an agonist of the estrogen-related receptors (ERRα, ERRβ and ERRγ). This receptor family is associated with the metabolic adaptations that follow endurance exercise, which is why SLU-PP-332 is frequently described in the literature as an exercise mimetic. Current research on the compound is preclinical, consisting of animal and cell-based studies rather than human clinical trials.
Research investigates SLU-PP-332 as a pan-ERR agonist, meaning it has been studied for activity across the estrogen-related receptors that govern oxidative metabolic programmes. Studies have examined its effects on mitochondrial biogenesis and on the shift toward oxidative, fat-burning metabolism typically seen in endurance-trained tissue. One published study reported that the acute aerobic exercise response it induced in animals was dependent on ERRα.
Published animal studies have examined SLU-PP-332 in relation to aerobic exercise capacity, metabolic syndrome, mitochondrial dysfunction and inflammation in the aging kidney, and cardiac fatty acid metabolism in heart failure models. A pilot study has also explored ERR targeting against age-related muscle atrophy linked to physical inactivity. Chemical optimization work has used SLU-PP-332 as a starting point to gain further insight into estrogen-related receptor signaling.
Human safety data for SLU-PP-332 are limited, as no controlled human studies are available. Adverse events are not summarized in the cited animal studies. Analytical chemistry groups have characterized its in vitro metabolites for doping-control purposes, reflecting interest from anti-doping laboratories in detecting ERR agonists described as having doping potential. Its long-term effects in humans have not been established.
Research protocols have used 500 to 1,500 mcg per administration by the subcutaneous route, once daily in the morning in a fasted state, in 8-week blocks followed by 4 weeks off. These figures describe what protocols have used and are not a recommendation. Each CoreX order ships with a protocol guide for laboratory reference.
Ask about SLU-PP-332
Our research assistant answers questions about the science, the studied ranges, and our products. It can be wrong, and it does not give medical advice.
Shop research compounds
Every batch is independently tested for identity and purity, and the certificate of analysis is tied to the lot number on your label.
Browse the shop







